TABLE 6

Pharmacokinetic parameters of finasteride and M3 after intrajejunal administration with (T2) and without (T1) ketoconazole coadministration

n = 5.

FinasterideM3
T1T2RatioaT1T2Ratioa
AUC0–6 h (μM · h)
    VP2.9 ± 2.16.3 ± 0.7*3 (1–15)1.2 ± 0.50.3 ± 0.1**0.2 (0.1–0.8)
    VH1.6 ± 1.44.1 ± 0.2*4 (1–33)1.4 ± 0.60.4 ± 0.2*0.3 (0.1–1.2)
    VF1.7 ± 1.14.4 ± 0.5**3 (1–10)1.3 ± 0.60.3 ± 0.1*0.2 (0.1–1.0)
Cmax (μM)
    VP2.6 ± 1.63.1 ± 0.70.5 ± 0.30.1 ± 0.1
    VH1.0 ± 0.51.4 ± 0.40.5 ± 0.30.1 ± 0.1*
    VF0.6 ± 0.31.2 ± 0.2**0.5 ± 0.30.1 ± 0.1
tmax (h)b
    VP0.3 (0.2–0.5)0.3 (0.3–0.5)1 (1–4)6 (4–6)
    VH0.5 (0.4–0.7)1.0 (0.5–1.0)1 (1–6)6 (3–6)*
    VF0.9 (0.5–1.5)1.5 (1.0–1.5)*1 (1–6)5 (5–6)
t1/2 (h)c
    VP1.5 ± 0.43.9 ± 1.1*
    VH1.7 ± 0.93.6 ± 0.8*
    VF1.6 ± 0.44.0 ± 1.1*
t1/2, abs (min)d
    VP2 ± 14 ± 2*
    VF7 ± 822 ± 7*
ka (1/h)d
    VP30 ± 1312 ± 5*
    VF12 ± 102 ± 1
k01 (1/h)e
    VP19 ± 1629 ± 28
    VF6 ± 53 ± 1

  • ↵* p < 0.05 (for significant difference between T1 and T2).

  • ↵** p < 0.01.

  • ↵a Data are average (range).

  • ↵b Data are median (range).

  • ↵c n = 4.

  • ↵d From deconvolution.

  • ↵e One-compartment analyses.